May 6, 2020 / 12:09 PM / 23 days ago

BRIEF-Iveric Bio Posts Q1 Loss Per Share Of $0.28

May 6 (Reuters) - Iveric Bio Inc:

* IVERIC BIO REPORTS FIRST QUARTER 2020 OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

* Q1 LOSS PER SHARE $0.28

* AS OF MARCH 31, 2020, CO HAD $108.4 MILLION IN CASH AND CASH EQUIVALENTS

* IVERIC BIO - ESTIMATES THAT ITS YEAR-END 2020 CASH, CASH EQUIVALENTS WILL RANGE BETWEEN $65 MILLION AND $70 MILLION

* IVERIC BIO - ESTIMATES CASH, CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS, CAPEX REQUIREMENTS AS CURRENTLY PLANNED INTO BEGINNING OF 2022

* IVERIC BIO - EXPECTS TOPLINE 18-MONTH DATA FROM FIRST PHASE 3 CLINICAL TRIAL EVALUATING ZIMURA FOR TREATMENT OF GA SECONDARY TO AMD, OPH2003, TO BE AVAILABLE BY END OF Q2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below